Daniel Bushyhead1, David Goldberg2. 1. Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 2. Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.; Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Abstract
PURPOSE OF REVIEW: The purpose of this article is to review recent literature regarding the use of Hepatitis C virus (HCV) positive donor livers in liver transplantation. Given the prevalence of HCV-positive patients on the waitlist coupled with high waitlist mortality, use of HCV-positive livers may be a means to meet patient needs. This review seeks to primarily answer the following questions: can HCV-positive livers be used safely and effectively? Are new direct acting antiviral medications safe and effective in HCV-positive liver recipients? RECENT FINDINGS: Use of HCV-positive donor livers for liver transplantation in HCV-positive recipients is increasing. These donor livers have equivalent patient and graft survival when compared to HCV-negative donor livers in HCV-positive liver transplant recipients. Recent studies suggest that use of direct acting antiviral medications in HCV-positive liver transplant recipients can be successful, although there is insufficient data for their use in recipients of HCV-positive donor livers. SUMMARY: HCV-positive donor livers may be safely and effectively used in HCV-positive liver transplant recipients. Direct acting antiviral medications appear safe and effective in HCV-positive liver transplant recipients, but data on their efficacy in HCV-positive liver transplant recipients are limited. Future research should focus on the use of HCV-positive donor livers in HCV-negative liver transplant recipients.
PURPOSE OF REVIEW: The purpose of this article is to review recent literature regarding the use of Hepatitis C virus (HCV) positive donor livers in liver transplantation. Given the prevalence of HCV-positive patients on the waitlist coupled with high waitlist mortality, use of HCV-positive livers may be a means to meet patient needs. This review seeks to primarily answer the following questions: can HCV-positive livers be used safely and effectively? Are new direct acting antiviral medications safe and effective in HCV-positive liver recipients? RECENT FINDINGS: Use of HCV-positive donor livers for liver transplantation in HCV-positive recipients is increasing. These donor livers have equivalent patient and graft survival when compared to HCV-negative donor livers in HCV-positive liver transplant recipients. Recent studies suggest that use of direct acting antiviral medications in HCV-positive liver transplant recipients can be successful, although there is insufficient data for their use in recipients of HCV-positive donor livers. SUMMARY:HCV-positive donor livers may be safely and effectively used in HCV-positive liver transplant recipients. Direct acting antiviral medications appear safe and effective in HCV-positive liver transplant recipients, but data on their efficacy in HCV-positive liver transplant recipients are limited. Future research should focus on the use of HCV-positive donor livers in HCV-negative liver transplant recipients.
Entities:
Keywords:
HCV-positive liver transplantation; HCV-positive livers; HCV-positive organs; Hepatitis C virus; direct acting antivirals; liver transplantation
Authors: Jacqueline G O'Leary; Michael A Neri; James F Trotter; Gary L Davis; Göran B Klintmalm Journal: Transpl Int Date: 2012-05-30 Impact factor: 3.782
Authors: Patrick G Northup; Curtis K Argo; Dennis T Nguyen; Maureen A McBride; Sean C Kumer; Timothy M Schmitt; Timothy L Pruett Journal: Transpl Int Date: 2010-10 Impact factor: 3.782
Authors: Xavier Forns; Michael Charlton; Jill Denning; John G McHutchison; William T Symonds; Diana Brainard; Theo Brandt-Sarif; Paul Chang; Valerie Kivett; Lluís Castells; Martín Prieto; Robert J Fontana; Thomas F Baumert; Audrey Coilly; Maria Carlota Londoño; François Habersetzer Journal: Hepatology Date: 2015-03-20 Impact factor: 17.425
Authors: Barna D Tugwell; Priti R Patel; Ian T Williams; Katrina Hedberg; Feng Chai; Omana V Nainan; Ann R Thomas; Judith E Woll; Beth P Bell; Paul R Cieslak Journal: Ann Intern Med Date: 2005-11-01 Impact factor: 25.391
Authors: M G Bowring; L M Kucirka; A B Massie; X Luo; A Cameron; M Sulkowski; K Rakestraw; A Gurakar; I Kuo; D L Segev; C M Durand Journal: Am J Transplant Date: 2016-08-24 Impact factor: 8.086
Authors: Michael Charlton; Edward Gane; Michael P Manns; Robert S Brown; Michael P Curry; Paul Y Kwo; Robert J Fontana; Richard Gilroy; Lewis Teperman; Andrew J Muir; John G McHutchison; William T Symonds; Diana Brainard; Brian Kirby; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Didier Samuel; Xavier Forns; Norah A Terrault Journal: Gastroenterology Date: 2014-10-07 Impact factor: 22.682
Authors: Meghan E Sise; Ian A Strohbehn; Emily Bethea; Jenna L Gustafson; Raymond T Chung Journal: Curr Opin Organ Transplant Date: 2019-06 Impact factor: 2.640
Authors: Ashton A Shaffer; Alvin G Thomas; Mary Grace Bowring; Sarah E Van Pilsum Rasmussen; Ayla Cash; Lauren M Kucirka; Saleh A Alqahtani; Ahmet Gurakar; Mark S Sulkowski; Andrew M Cameron; Dorry L Segev; Christine M Durand Journal: Transpl Infect Dis Date: 2018-09-21 Impact factor: 2.228
Authors: Schnegg Bruno; Bart Nicole; Dharan Nila J; Matthews Gail; Nadel James; Macdonald Peter S; Hayward Christopher S Journal: Transplant Direct Date: 2019-08-23